The prognostic value of SII (Systemic Immune-Inflammation Index) in HER-2-positive breast
cancer (BC) patients, regardless of whether they receive trastuzumab treatment, and its …

Purpose Neutrophils and platelets have been described as tumor-promoting factors, but
lymphocytes have been described as tumor-inhibiting factors. The prognostic values of the …

Background The relationship of neutrophil/lymphocyte ratio (NLR) to prognosis of HER2-
positive breast cancer (BC) is not well studied. We aimed to assess the prognostic role of …

Purpose: We sought to examine the role of pretreatment systemic immune-inflammation
index (SII) in hormone receptor-negative, human epidermal growth factor receptor …

Background The prognosis of patients who can achieve a complete response after
neoadjuvant chemotherapy could be significantly improved. Thus, accurately predicting the …

Trastuzumab emtansine (T-DM1) is a mainstay therapy for HER2-positive metastatic breast
cancer (mBC). However, identifying patients who will benefit most remains a challenge due …

Simple Summary Although taxane-trastuzumab-pertuzumab combinations in the first-line
treatment setting significantly improved clinical outcomes in patients with Human Epidermal …

Background: Immune responses play an important role in the development of breast cancer.
Trastuzumab can activate antibody-dependent cellular cytotoxicity (ADCC) in human …

Approximately half of all HER2/neu-overexpressing breast cancer patients do not respond to
trastuzumab-containing therapy. Therefore, there remains an urgent and unmet clinical need …

Background Peripheral blood inflammation indices, including the neutrophil-to-lymphocyte
ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index …